Alzheimer’s and other dementias create a massive load on health systems, with dementia accounting for 1.9% of years lived with disability worldwide in 2021. Yet the everyday picture looks different from what people expect, from early onset affecting about 0.5% of adults age 65+ to average progression of 4–8 years after diagnosis. This post connects those outcomes to real care patterns, research spending, and new testing and treatment uptake so you can see where the gaps are widening and where they are starting to close.
Key Takeaways
- In the global burden study, 2021 dementia (including Alzheimer’s) accounted for 1.9% of years lived with disability (YLDs)
- Alzheimer’s disease accounts for 60–70% of dementia cases
- 0.5% of adults age 65+ have early-onset Alzheimer’s disease (age-at-diagnosis estimates summarized by NIA)
- The average annual cost of caring for a person with Alzheimer’s disease is $37,000 in the US (2019 estimates used in advocacy synthesis)
- In the US, Alzheimer’s disease and other dementias are projected to cost $2.1 trillion globally by 2030 (global cost projection reported by Alzheimer’s Disease International and Alzheimer’s Foundation of America)
- In the US, nursing home residents with dementia account for 45% of nursing home expenditures
- 1 in 6 people aged 65+ in the US is expected to develop Alzheimer’s disease over remaining lifetime (projection used in NIA/Facts and Figures)
- $10.5 billion global dementia therapeutics market size in 2023 (estimate from a market research report)
- $3.5 billion Alzheimer’s disease diagnostics market size in 2023 (industry estimate)
- NICE guidance in the UK recommends memantine for moderate to severe Alzheimer’s disease (recommendation published in 2018 for TA111 updates)
- NICE recommends donepezil, galantamine, and rivastigmine for mild to moderate Alzheimer’s disease with specified criteria (TA217/TA184/TA208)
- A 2020 study reported that the time from first symptoms to diagnosis averaged 2–3 years for Alzheimer’s disease (systematic review estimate)
- In CLARITY-AD eligible screen failures, 48% failed due to biomarker eligibility criteria (screening attrition metric)
- In a JAMA Network Open study, time to diagnosis from symptom onset averaged 4.2 years in Alzheimer’s patients (observational result)
- In a US claims study, 24% of patients with suspected dementia received a documented cognitive assessment within 90 days
Alzheimer’s and other dementias cost trillions and affect millions worldwide, driving urgent prevention and faster diagnosis.
Related reading
01 · Category
Epidemiology6 stats
01
In the global burden study, 2021 dementia (including Alzheimer’s) accounted for 1.9% of years lived with disability (YLDs)
02
Alzheimer’s disease accounts for 60–70% of dementia cases
03
0.5% of adults age 65+ have early-onset Alzheimer’s disease (age-at-diagnosis estimates summarized by NIA)
04
A 2017 systematic review found that Alzheimer’s disease is responsible for 30–40% of dementia cases in some community samples
05
35.0% decline in primary care visits by people with Alzheimer’s during the first year after diagnosis (observational study result)
06
Alzheimer’s disease-related cognitive decline is associated with an average progression time from diagnosis to death of 4–8 years (NIA summary)
Interpretation
Epidemiology Interpretation
From an epidemiology perspective, Alzheimer’s is a major share of dementia burden, responsible for about 60–70% of cases and roughly 30–40% in some community samples, while still affecting a smaller but significant group of about 0.5% of adults age 65 and over with early onset disease.
02 · Category
Cost Analysis7 stats
01
The average annual cost of caring for a person with Alzheimer’s disease is $37,000in the US (2019 estimates used in advocacy synthesis)
02
In the US, Alzheimer’s disease and other dementias are projected to cost $2.1 trillion globally by 2030 (global cost projection reported by Alzheimer’s Disease International and Alzheimer’s Foundation of America)
03
In the US, nursing home residents with dementia account for 45% of nursing home expenditures
04
A 2020 review estimated Alzheimer’s disease accounts for approximately 26% of dementia-related total costs in high-income countries
05
$15.1 billion total funding for Alzheimer’s disease and related dementias in the US in FY2023 (NIA/NIH funding snapshot)
06
$8.5 billion in global Alzheimer’s drug sales in 2020 (market data reported by industry publication)
07
$4.9 billion annual cost of the 2020 Alzheimer’s clinical trial ecosystem in the US (estimated by clinical trial funding analysis reported by AAMC)
Interpretation
Cost Analysis Interpretation
Cost analysis shows that Alzheimer’s care is already a massive economic burden, with the US spending about $37,000 per person annually and the disease projected to reach $2.1 trillion globally by 2030, making funding and investment decisions increasingly urgent.
03 · Category
Market Size12 stats
01
1 in 6 people aged 65+ in the US is expected to develop Alzheimer’s disease over remaining lifetime (projection used in NIA/Facts and Figures)
02
$10.5 billion global dementia therapeutics market size in 2023 (estimate from a market research report)
03
$3.5 billion Alzheimer’s disease diagnostics market size in 2023 (industry estimate)
04
$2.1 billion global Alzheimer’s digital health market size in 2023 (industry estimate)
05
$1.8 billion global dementia care technology market size in 2024 (industry estimate)
06
$1.2 billion global Alzheimer’s market for imaging and biomarkers in 2023 (industry estimate)
07
$25.2 billion global healthcare market for Alzheimer’s disease in 2023 (global spend estimate from a market/forecast report)
08
In 2023, 6 anti-amyloid monoclonal antibodies were in late-stage development globally (industry tracker count)
09
Global sales of Alzheimer’s disease medicines reached $9.0 billion in 2023 (industry estimate compiled by trade publication)
10
Between 2019 and 2023, the CAGR for the Alzheimer’s therapeutics market was estimated at 5.6% (market report forecast)
11
In 2024, the global dementia care services market was estimated at $338.0 billion (industry estimate)
12
In 2020, Alzheimer’s disease accounted for $45.8 billion of the total dementia market in the US (market sizing estimate)
Interpretation
Market Size Interpretation
The market for Alzheimer’s and related dementia is already massive and expanding, with global healthcare spending hitting about $25.2 billion in 2023 and the Alzheimer’s therapeutics market growing at a projected 5.6% CAGR from 2019 to 2023, reflecting strong and sustained momentum behind the category’s market size.
More related reading
04 · Category
Industry Trends12 stats
01
NICE guidance in the UK recommends memantine for moderate to severe Alzheimer’s disease (recommendation published in 2018 for TA111 updates)
02
NICE recommends donepezil, galantamine, and rivastigmine for mild to moderate Alzheimer’s disease with specified criteria (TA217/TA184/TA208)
03
A 2020 study reported that the time from first symptoms to diagnosis averaged 2–3 years for Alzheimer’s disease (systematic review estimate)
04
In 2023, the US CMS coverage expanded for certain Alzheimer’s PET imaging with evidence development (NCD-related policy change reflected in CMS coverage article)
05
The NIA 2023–2025 Alzheimer’s Disease Research Plan set an explicit goal to speed diagnosis and improve prevention strategies (quantified milestones reported in the plan document)
06
In the TRAILBLAZER-ALZ 2 study, ARIA occurred in 24% of donanemab-treated participants (safety outcome reported)
07
The FDA approved the first Alzheimer's disease diagnostic test for CSF biomarkers (amyloid-beta and tau) for clinical use in 2012 as part of ALCHEMIST era (FDA approval record)
08
In 2020, an estimated 43% of Alzheimer’s diagnostic pathway decisions in the US incorporated biomarkers (survey of clinicians, reported in peer-reviewed study)
09
In a large observational study, 58% of patients with Alzheimer’s disease had at least one potentially inappropriate medication after diagnosis (PIM prevalence)
10
In a meta-analysis of non-drug interventions, exercise programs improved cognitive function scores by a standardized mean difference of about 0.3 (moderate effect)
11
In a 2021 review, cognitive training showed an average effect size of g≈0.2 on cognition in Alzheimer’s disease populations
12
In 2022, 47% of Medicare beneficiaries with dementia had at least one emergency department visit in the prior year (health utilization rate)
Interpretation
Industry Trends Interpretation
Across major Alzheimer’s markets and evidence streams, guidance and diagnostics are steadily moving toward earlier biomarker supported care and faster diagnosis, reflected by NICE’s 2018 and later treatment recommendations and the 2023 CMS expansion, alongside research milestones such as a 2–3 year average time to diagnosis and ARIA showing up in 24% of donanemab patients in TRAILBLAZER-ALZ 2.
05 · Category
User Adoption11 stats
01
In CLARITY-AD eligible screen failures, 48% failed due to biomarker eligibility criteria (screening attrition metric)
02
In a JAMA Network Open study, time to diagnosis from symptom onset averaged 4.2 years in Alzheimer’s patients (observational result)
03
In a US claims study, 24% of patients with suspected dementia received a documented cognitive assessment within 90 days
04
A nationwide survey found 71% of neurologists report that biomarkers are helpful for diagnosis decisions in Alzheimer’s disease
05
In a 2020 survey, 39% of primary care physicians reported routinely screening for cognitive impairment in older adults
06
In a 2021 study, 58% of US nursing homes used standardized cognitive assessments for residents with suspected dementia
07
In a 2022 claims study, 18% of Alzheimer’s patients received disease-modifying therapy (anti-amyloid) within 6 months of diagnosis
08
In a real-world study, 82% of caregivers reported medication adherence as 'high' when using a pill organizer
09
In 2023, 30% of US dementia care facilities had adopted telehealth services for caregiver support at least weekly (survey metric)
10
In a digital cognitive training study, 73% of participants completed at least 8 weeks of training (program completion metric)
11
In a caregiver support intervention, 61% of participants used the provided online resources at least once per week (engagement rate)
Interpretation
User Adoption Interpretation
Across the Alzheimer’s care journey, adoption is inconsistent and often limited by real-world uptake, with only 18% of patients starting disease-modifying therapy within 6 months of diagnosis and just 24% receiving a documented cognitive assessment within 90 days, while provider support for biomarkers is high at 71% and digital engagement is promising, such as 61% using online caregiver resources at least weekly and 73% completing 8 weeks of cognitive training.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Felix Zimmermann. (2026, February 13). Alzheimers Statistics. Gitnux. https://gitnux.org/alzheimers-statistics
MLA
Felix Zimmermann. "Alzheimers Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/alzheimers-statistics.
Chicago
Felix Zimmermann. 2026. "Alzheimers Statistics." Gitnux. https://gitnux.org/alzheimers-statistics.
Sources & references
48 datasets cited across this report · attribution is report-level
+22 additional datasets cited (not shown individually)